Selective Sphingosine 1 Phosphate Receptor Modulators And Methods Of Chiral Synthesis

Patent No. EP2498610 (titled "Selective Sphingosine 1 Phosphate Receptor Modulators And Methods Of Chiral Synthesis") was filed by Celgene II on Nov 15, 2010. The application was issued on Jun 19, 2024.

Patent Summary

Compounds that selectively activate the sphingosine 1-phosphate receptor subtype 1 (S1P1) for treating inflammatory bowel disease (IBD) and other conditions, including multiple sclerosis, transplant rejection, and acute respiratory distress syndrome. The compounds have a specific indane or oxadiazole-indane structure and are synthesized through a chiral synthesis method that produces enantiomerically enriched compounds.

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
GENERICS UKDec 14, 2018ELKINGTON AND FIFE

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP2498610

CELGENE II
Application Number
EP10830880A
Filing Date
Nov 15, 2010
Status
Patent Maintained As Amended
May 17, 2024
Publication Date
Jun 19, 2024